Vorinostat and Low Dose Cytarabine for High Risk Myelodysplasia
Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the maximum tolerated duration and schedule of oral
VORINOSTAT in addition to low dose cytarabine in the treatment of Intermediate-2 and High
risk myelodysplastic syndromes.